Sep 16, 2026
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Sunshine Biopharma announced it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The candidate demonstrated nanomolar potency against the viral protease and broad-spectrum activity against SARS-CoV-2 variants, showing high oral bioavailability and preferential lung enrichment in animal models. CEO Steve Slilaty highlighted its competitive profile for future coronavirus therapeutics, alongside the company's progress in its oncology initiative.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 16, 2026
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Sunshine Biopharma Inc. has advanced its lead Coronavirus drug candidate, a potent PLpro inhibitor, into IND-enabling studies. The drug candidate demonstrates nanomolar potency against SARS-CoV-2 variants, strong oral bioavailability, preferential lung enrichment, and dose-dependent suppression of pulmonary viral replication in vivo. This development positions the company to potentially introduce a new generation of coronavirus therapeutics.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 16, 2026
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Sunshine Biopharma Inc. announced its lead coronavirus drug candidate is advancing into IND-enabling studies. The candidate demonstrated potent inhibition against SARS-CoV-2 variants, strong oral bioavailability, and dose-dependent viral suppression. Additionally, the company provided an update on its K1.1 mRNA lipid nanoparticle oncology program, which showed promising preclinical results in targeting tumor suppressor expression.
Company relevance
98.82%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish